Logo

Innovent's Byvasda (biosimilar- bevacizumab) Receives NMPA's Approval for the Treatment of Adult Recurrent Glioblastoma

Share this

Innovent's Byvasda (biosimilar- bevacizumab) Receives NMPA's Approval for the Treatment of Adult Recurrent Glioblastoma

Shots:

  • The indication is the third indication approved for the therapy- previously it was approved for advanced NSCLC and metastatic colorectal cancer
  • The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
  • Byvasda is an anti -VEGF humanized mAb. In Jan’2020- Innovent out-licensed the commercial rights of the biosimilar in the US and Canada to Coherus BioSciences

 ­ Ref: PRNewswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions